An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives

Cabozantinib is an oral tyrosine kinase inhibitor (TKI) with activity against several receptors involved in the angiogenesis pathway, including vascular endothelial growth factor receptor (VEGFR), c-MET and AXL. The antiangiogenic properties of cabozantinib led to its use as a monotherapy for the tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Iaxx, Romain, Lefort, Felix, Domblides, Charlotte, Ravaud, Alain, Bernhard, Jean-Christophe, Gross-Goupil, Marine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169675/
https://www.ncbi.nlm.nih.gov/pubmed/35677148
http://dx.doi.org/10.2147/TCRM.S251673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169675/
https://www.ncbi.nlm.nih.gov/pubmed/35677148
http://dx.doi.org/10.2147/TCRM.S251673

Ejemplares similares